196 related articles for article (PubMed ID: 27393627)
1. Irreversible electroporation enhances delivery of gemcitabine to pancreatic adenocarcinoma.
Bhutiani N; Agle S; Li Y; Li S; Martin RC
J Surg Oncol; 2016 Aug; 114(2):181-6. PubMed ID: 27393627
[TBL] [Abstract][Full Text] [Related]
2. Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma.
Bhutiani N; Li Y; Zheng Q; Pandit H; Shi X; Chen Y; Yu Y; Pulliam ZR; Tan M; Martin RCG
Ann Surg Oncol; 2020 Oct; 27(11):4348-4359. PubMed ID: 32681477
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of combination of induction chemotherapy and irreversible electroporation ablation for patients with locally advanced pancreatic adenocarcinoma.
Huang KW; Yang PC; Pua U; Kim MD; Li SP; Qiu YD; Song TQ; Liang PC
J Surg Oncol; 2018 Jul; 118(1):31-36. PubMed ID: 29878378
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic Adenocarcinoma Treated With Irreversible Electroporation Case Report: First Experience and Outcome.
Trueba-Arguiñarena FJ; de Prado-Otero DS; Poves-Alvarez R
Medicine (Baltimore); 2015 Jul; 94(26):e946. PubMed ID: 26131840
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factor analysis of irreversible electroporation for locally advanced pancreatic cancer - A multi-institutional clinical study in Asia.
Yang PC; Huang KW; Pua U; Kim MD; Li SP; Li XY; Liang PC
Eur J Surg Oncol; 2020 May; 46(5):811-817. PubMed ID: 31839436
[TBL] [Abstract][Full Text] [Related]
6. Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer: Our preliminary experience.
Belfiore MP; Ronza FM; Romano F; Ianniello GP; De Lucia G; Gallo C; Marsicano C; Di Gennaro TL; Belfiore G
Int J Surg; 2015 Sep; 21 Suppl 1():S34-9. PubMed ID: 26118600
[TBL] [Abstract][Full Text] [Related]
7. Effects of calcium electroporation, electrochemotherapy, and irreversible electroporation on quality of life and progression-free survival in patients with pancreatic cancer: IREC clinical study.
Rudno-Rudzińska J; Kielan W; Guziński M; Kulbacka J
Adv Clin Exp Med; 2021 Jul; 30(7):765-770. PubMed ID: 34313408
[TBL] [Abstract][Full Text] [Related]
8. New therapeutic strategy: Personalization of pancreatic cancer treatment-irreversible electroporation (IRE), electrochemotherapy (ECT) and calcium electroporation (CaEP) - A pilot preclinical study.
Rudno-Rudzińska J; Kielan W; Guziński M; Płochocki M; Antończyk A; Kulbacka J
Surg Oncol; 2021 Sep; 38():101634. PubMed ID: 34303953
[TBL] [Abstract][Full Text] [Related]
9. Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study.
Vogel JA; Rombouts SJ; de Rooij T; van Delden OM; Dijkgraaf MG; van Gulik TM; van Hooft JE; van Laarhoven HW; Martin RC; Schoorlemmer A; Wilmink JW; van Lienden KP; Busch OR; Besselink MG
Ann Surg Oncol; 2017 Sep; 24(9):2734-2743. PubMed ID: 28560601
[TBL] [Abstract][Full Text] [Related]
10. Irreversible electroporation in locally advanced pancreatic cancer: A call for standardization of energy delivery.
Martin RC; Durham AN; Besselink MG; Iannitti D; Weiss MJ; Wolfgang CL; Huang KW
J Surg Oncol; 2016 Dec; 114(7):865-871. PubMed ID: 27546233
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.
Zagon IS; Jaglowski JR; Verderame MF; Smith JP; Leure-Dupree AE; McLaughlin PJ
Cancer Chemother Pharmacol; 2005 Nov; 56(5):510-20. PubMed ID: 15947928
[TBL] [Abstract][Full Text] [Related]
12. Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.
Damaraju VL; Bouffard DY; Wong CK; Clarke ML; Mackey JR; Leblond L; Cass CE; Grey M; Gourdeau H
BMC Cancer; 2007 Jul; 7():121. PubMed ID: 17608948
[TBL] [Abstract][Full Text] [Related]
13. Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study.
Ruarus AH; Vroomen LGPH; Geboers B; van Veldhuisen E; Puijk RS; Nieuwenhuizen S; Besselink MG; Zonderhuis BM; Kazemier G; de Gruijl TD; van Lienden KP; de Vries JJJ; Scheffer HJ; Meijerink MR
Radiology; 2020 Jan; 294(1):212-220. PubMed ID: 31687922
[TBL] [Abstract][Full Text] [Related]
14. Concurrent chemotherapy alone versus irreversible electroporation followed by chemotherapy on survival in patients with locally advanced pancreatic cancer.
Belfiore G; Belfiore MP; Reginelli A; Capasso R; Romano F; Ianniello GP; Cappabianca S; Brunese L
Med Oncol; 2017 Mar; 34(3):38. PubMed ID: 28161827
[TBL] [Abstract][Full Text] [Related]
15. Investigation of safety for electrochemotherapy and irreversible electroporation ablation therapies in patients with cardiac pacemakers.
Jarm T; Krmac T; Magjarevic R; Kos B; Cindric H; Miklavcic D
Biomed Eng Online; 2020 Nov; 19(1):85. PubMed ID: 33198769
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
Maggino L; Malleo G; Marchegiani G; Viviani E; Nessi C; Ciprani D; Esposito A; Landoni L; Casetti L; Tuveri M; Paiella S; Casciani F; Sereni E; Binco A; Bonamini D; Secchettin E; Auriemma A; Merz V; Simionato F; Zecchetto C; D'Onofrio M; Melisi D; Bassi C; Salvia R
JAMA Surg; 2019 Oct; 154(10):932-942. PubMed ID: 31339530
[TBL] [Abstract][Full Text] [Related]
17. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation.
Kwon D; McFarland K; Velanovich V; Martin RC
Surgery; 2014 Oct; 156(4):910-20. PubMed ID: 25239345
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
[TBL] [Abstract][Full Text] [Related]
19. An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: potential application for preclinical studies.
Mohammad RM; Al-Katib A; Pettit GR; Vaitkevicius VK; Joshi U; Adsay V; Majumdar AP; Sarkar FH
Clin Cancer Res; 1998 Apr; 4(4):887-94. PubMed ID: 9563882
[TBL] [Abstract][Full Text] [Related]
20. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
Réjiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A
Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
